Plagens RN, Tirado CSR, Li S, Maldonado-Vazquez N, Montes-Rodriguez IM, Dutil J, Mills CA, Herring LE, Franco HL. Mapping the FOXA1 Interactome in ER+ Breast Cancer Cells Using Proximity Labeling Reveals Novel Interactions with the Orphan Nuclear Receptor NR2C2. Mol Cancer Res. 2025 Dec 02; 23(12):997-1011.

Xia K, Chen E, Hu R, Pagano I, Fukui J. Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii. Breast J. 2025; 2025:9104103.

Belgodere JA, Elliott JR, Benz MC, Kpeli GW, Elliott S, Ponder IJ, Sanga Pema GER, Ma P, Dietrich SR, Cheng T, Nguyen K, Tilghman SL, Zou B, Anbalagan M, Rowan BG, Newman RH, Mondrinos M, Sridhar J, Wiese TE, Ali S, Hoang VT, Collins-Burow BM, Martin EC, Abbas HK, Bou? SM, Burow ME. Modulation of Estrogen Receptor Activity by the Phytoalexin Tuberosin Produced from Elicited Kudzu (Pueraria lobata). J Nat Prod. 2025 Jul 25; 88(7):1568-1580.

Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776.

Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, K?bel M, Meagher NS, Na R, Antoniou AC, Brand AH, Kennedy CJ, Nevins N, Pharoah PDP, Shvetsov YB, Winham SJ, Alsop J, Beckmann MW, Bolithon A, Boros J, Bowtell DDL, Brenton JD, Carney ME, Chudecka-Glaz A, Cook LS, Cybulski C, Fasching PA, Fereday S, Fortner RT, Garc?a MJ, Goode EL, Goodman MT, Gronwald J, Hartmann A, Hernandez BY, H?gdall E, Huntsman DG, Jensen A, Jimenez-Linan M, Joseph JM, Karlan BY, Kaznowska E, Kjaer SK, Kluz T, Koziak JM, Lester J, Longacre TA, Lycke M, McGuire V, Moysich KB, Murphy RA, Orsulic S, Ramus SJ, Rodr?guez-Antona C, Rothstein JH, Samra S, Sieh W, Steed H, Sundfeldt K, Talhouk A, Ucinski J, Wang C, Wentzensen N, Whittemore AS, Wilkens LR, Songer T, Brooks MM, Tang L, Modugno F. Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis. Gynecol Oncol. 2025 Jul; 198:112-129.

Lantz AE, Gordi?n ER, Rosa M, Rodr?guez-Ru?z M, Johnson JO, Gebert R, Bahr A, Chen DT, Dutil J, Li J, Oliveras Torres JA, Saavedra HI, Eschrich SA, Flores I, Cress WD. Creation and Characterization of a Breast Cancer Tissue Microarray Including Black and White Patients from Florida and Hispanic Patients from Puerto Rico and Florida. Cancer Res Commun. 2025 May 01; 5(5):804-813.

Jones V, Yin HH, Yuan YC, Wang Y, Li SM, Aljaber D, Sanchez A, Quinones C, Schmolze D, Yuan Y, Mortimer J, Yee L, Kruper L, Jovanovic-Talisman T, Tomsic J, Sanchez N, Chavez T, O'Regan RM, Khan QJ, Davis M, Kalinsky K, Meisel J, Kittles R, Rodriguez-Rodriguez L, Seewaldt V. Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer. Sci Rep. 2025 Feb 28; 15(1):7220.

Chattopadhyay M, Nath N, Kodela R, Metkar S, Soyemi SA, Kashfi K. NOSH-aspirin (NBS-1120) inhibits estrogen receptor-negative breast cancer in?vitro and in?vivo by modulating redox-sensitive signaling pathways. J Pharmacol Exp Ther. 2025 Jan; 392(1):100019.

Wang Q, Huang N, Psaltis JB, Gahtani RM, Yan G, Lu D, Cahalan SR, Shi X, Copeland RL, Haddad BR, Martin MB. Activation of estrogen-related receptor ? by calcium and cadmium. Front Endocrinol (Lausanne). 2024; 15:1400022.

Hanafi D, Onyenwoke RU, Kimbro KS. The G-Protein-Coupled Estrogen Receptor Selective Agonist G-1 Attenuates Cell Viability and Migration in High-Grade Serous Ovarian Cancer Cell Lines. Int J Mol Sci. 2024 Jun 13; 25(12).